Catalyst Event
Regeneron Pharmaceuticals Inc (REGN) · Other
From KEDI Tesla Fixed Tech100 Index (KTSLT100)
3/24/2026, 12:00:00 AM
Regeneron and Sanofi announced Dupixent's approval in Japan for bullous pemphigoid on March 24, 2026; <5% impact estimated due to niche market expected.
Korean Translation
2026년 3월 24일 리제네론과 사노피의 듀피젠트가 일본에서 수포성 유사천포창 치료제로 승인되었으며, 틈새 시장 특성상 5% 미만의 주가 영향이 예상됨.
Related Recent Events
Biogen Inc (BIIB) · Other
FDA PDUFA action date for the supplemental Biologics License Application (sBLA) for a subcutaneous formulation of LEQEMBI is May 24, 2026; Medium importance is estimated due to uncertain market reaction scheduled.
5/24/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 2027 earnings release is scheduled for May 20, 2026; Medium importance is assigned as earnings typically drive 5-10% volatility, and analysts forecast an EPS of $1.74-$1.76 estimated.
5/20/2026, 12:00:00 AM
Amgen Inc (AMGN) · Other
A quarterly dividend of $2.52 per share for Q2 2026 is scheduled, with an ex-dividend date of May 15, 2026; a price impact of ≥1% is estimated due to the routine nature of the distribution, scheduled.
5/15/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Q1 2026 earnings release is scheduled. High importance estimated due to expected market volatility.
5/13/2026, 12:00:00 AM
Fortinet Inc (FTNT) · Earnings Release
Analysts forecast EPS of approximately $0.62 forecasted. Q1 2026 earnings release scheduled. Low impact expected for routine announcement.
5/6/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
Q1 2026 earnings release is scheduled for May 5, 2026, with analysts forecasting EPS of approximately $1.27, estimated. Medium importance is estimated as earnings reports typically drive significant price volatility, scheduled.
5/5/2026, 12:00:00 AM